Abstract:Background Glioblastoma is an aggressive primary brain malignancy that is characterized by a highly suppressive tumor microenvironment, including myeloid-derived suppressor cells, tumor-associated macrophages, and brain-resident microglia, but lacking significant T cell infiltration. 1 2 This phenotype is reflected in the recently developed QKi -/- Pten -/- P53 -/- (QPP) tumor model, 3 which we show is resistant to PD1 or CTLA-4 blockade, but sensitive to agonists of the innate immune sensor Stimulator of Interferon Genes (STING). We have previously shown that agonists of the innate dsDNA-sensing cGAS-STING pathway are capable of proinflammatory repolarization in in vitro models of suppressive myeloid cells, although their function in the context of the Glioblastoma myeloid compartment in vivo remains poorly understood. 4 Methods We utilized the synthetic cyclic di-nucleotide STING agonists IACS-8803 (8803) and ML-RR-S2-CDA (MLRR) to assess survival and tumor immune infiltrate functional reprogramming in two orthotopic transplantable human and murine Glioblastoma tumor models, U87 and the recently developed QPP8 (Qki -/- Pten -/- P53 -/- ). Using in vitro models of M2-polarized microglia, we investigated the ability of natural (2'3'-cGAMP) and synthetic (MLRR and 8803) STING agonists to reverse immunosuppressive microglial polarization. Results We found that intratumoral delivery of STING agonists significantly prolonged survival in the murine QPP8 orthotopic Glioblastoma tumor model, in contrast to checkpoint blockade which had no benefit on survival. In huNOG-EXL mice engrafted with human hematopoietic stem cells implanted with orthotopic U87 Glioblastoma, intratumoral delivery of STING agonists significantly prolonged survival and reduced expression of CD163 and CD206 on human tumor-infiltrating myeloid populations. Preliminary data suggests that in vitro suppressively-polarized microglia reduce expression of M2 functional markers, and increase expression of iNOS, PD-L1, CD80, and CD86 in a STING agonist potency-dependent manner. Conclusions We found that STING agonists can induce curative responses in checkpoint-refractory murine Glioblastoma models and mediate significant extension of survival in a humanized mouse U87 xenograft setting. This prolonged survival is associated with a decrease in immunosuppressive M2 functional markers in human tumor infiltrating myeloid populations. Additionally, M2-polarized microglia demonstrated a reduction in M2 functional markers and upregulation of proinflammatory M1 markers following treatment with STING agonists. Together these results indicate that delivery of STING agonists can induce proinflammatory repolarization of the Glioblastoma myeloid stroma, including both infiltrating myeloid populations and brain-resident microglia, to drive prolonged survival in refractory models of Glioblastoma. References Gabrusiewicz K, Rodriguez B, Wei J, et al. Glioblastoma-infiltrated innate immune cells resemble M0 macrophage phenotype. JCI Insight 2016; 1 (2). Quail DF, Joyce JA. The microenvironmental landscape of brain tumors. Cancer Cell 2017; 31 (3):326–41. Shingu T, Ho AL, Yuan L, et al. Qki deficiency maintains stemness of glioma stem cells in suboptimal environment by downregulating endolysosomal degradation. Nat Genet 2017; 49 (1):75–86. Ager C, Boda A, Rajapakshe K, et al. (2021) “High potency STING agonists engage unique myeloid pathways to reverse pancreatic cancer immune privilege. JITC (in press) Ethics Approval All experiments were conducted according to protocols approved by the University of Texas MD Anderson Cancer Center Institutional Animal Care and Use Committee.

STING is significantly increased in high-grade glioma with high risk of recurrence

Single-Cell Transcriptomics Reveals the Heterogeneity of the Immune Landscape of IDH-Wild-Type High-Grade Gliomas

763 Intratumoral delivery of high potency STING agonists modulates the immunosuppressive myeloid compartment and induces curative responses in checkpoint-refractory glioblastoma models

STING agonist 8803 reprograms the immune microenvironment and increases survival in preclinical models of glioblastoma

Investigating the impact of STING pathway activation on breast cancer treatment outcomes: development and validation of a prognostic model

Recurrence- and Malignant Progression-Associated Biomarkers in Low-Grade Gliomas and Their Roles in Immunotherapy

STING activation promotes robust immune response and NK cell–mediated tumor regression in glioblastoma models

A combination of RNA-Seq and CHIP-Seq analysis for determining super enhancer- associated genes to evaluate prognosis and immunity of glioma

Collagen Type III Alpha 1 Chain Regulated by GATA‐Binding Protein 6 Affects Type II IFN Response and Propanoate Metabolism in the Recurrence of Lower Grade Glioma

IMMU-34. ATRX MUTATIONS PREDICT RESPONSE TO INNATE BASED THERAPY IN GLIOMA

Immunohistochemical characterization of lymphangiogenesis-related biomarkers in primary and recurrent gliomas: A STROBE compliant article.

Prognostic Value and Oncogenic Role of STING-Related Genes GAB3 and IL16 in Lung Adenocarcinoma: Implications for Immune Evasion and Treatment

A longer time to relapse is associated with a larger increase in differences between paired primary and recurrent IDH wild-type glioblastomas at both the transcriptomic and genomic levels

Recombinant immunotoxin induces tumor intrinsic STING signaling against head and neck squamous cell carcinoma

Features and therapeutic potential of T-cell receptors in high-grade glioma

Immunogenicity of Small‐cell Lung Cancer Associates with STING Pathway Activation and is Enhanced by ATR and TOP1 Inhibition

A specific immune signature for predicting the prognosis of glioma patients with IDH1-mutation and guiding immune checkpoint blockade therapy

An Inflammatory Gene-Related Prognostic Risk Score Model for Prognosis and Immune Infiltration in Glioblastoma.

A Risk Model Developed Based on Homologous Recombination Deficiency Predicts Overall Survival in Patients With Lower Grade Glioma

Loss of STING Expression is Prognostic in Non–small Cell Lung Cancer

A novel Golgi related genes based correlation prognostic index can better predict the prognosis of glioma and responses to immunotherapy